Pain transduction: a pharmacologic perspective
نویسندگان
چکیده
منابع مشابه
Ipilimumab for advanced melanoma: A pharmacologic perspective
Ipilimumab, a fully human anti-CTLA-4 antibody, has been approved for the treatment of unresectable or metastatic melanoma based on its survival benefit demonstrated in randomized phase III studies. The current approved dosing schedule of ipilimumab is 3 mg/kg as a 90-min intravenous infusion every 3 weeks for a total of 4 doses. The immune-mediated mechanism of action of ipilimumab can result ...
متن کاملVitamin D supplementation: a pharmacologic perspective.
PURPOSE OF REVIEW Vitamin D supplementation is expected to increase as clinicians try to optimize their patients' vitamin D status. This review integrates newer information into a perspective on vitamin D disposition and effect. RECENT FINDINGS Vitamin D is being considered for indications beyond bone health. The limited dose-response data vary by indication, but generally target a goal serum...
متن کاملPharmacologic management of chronic pain.
Pain is associated with myriad medical conditions and affects millions of Americans. Chronic pain is one of the most common reasons prompting visits to healthcare providers; collectively, it possibly disables more people annually than heart disease and cancer combined. Primary goals of treating patients with chronic pain are to reduce pain as much as possible and facilitate functional restorati...
متن کاملPharmacologic Management of Chronic Pain
Chronic pain is a multifactorial condition with both physical and psychological symptoms, and it affects around 20% of the population in the developed world. In spite of outstanding advances in pain management over the past decades, chronic pain remains a significant problem. This article provides a mechanism- and evidence-based approach to improve the outcome for pharmacologic management of ch...
متن کاملPharmacologic therapy for acute pain.
The approach to patients with acute pain begins by identifying the underlying cause and a disease-specific treatment. The first-line pharmacologic agent for the symptomatic treatment of mild to moderate pain is acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). The choice between these two medications depends on the type of pain and patient risk factors for NSAID-related adverse ef...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Clinical Pharmacology
سال: 2016
ISSN: 1751-2433,1751-2441
DOI: 10.1080/17512433.2016.1183481